{"id":1527,"date":"2023-02-01T11:56:22","date_gmt":"2023-02-01T11:56:22","guid":{"rendered":"https:\/\/www.cic.vc\/?p=1527"},"modified":"2024-04-16T12:26:37","modified_gmt":"2024-04-16T12:26:37","slug":"sense-announces-agreement-to-be-acquired-by-sherlock-biosciences","status":"publish","type":"post","link":"https:\/\/www.cic.vc\/sense-announces-agreement-to-be-acquired-by-sherlock-biosciences\/","title":{"rendered":"Sense announces agreement to be acquired by Sherlock Biosciences"},"content":{"rendered":"<p><span class=\"text-small\">Sherlock Biosciences, a company engineering biology to bring next-generation diagnostics to the point of need, today announced the acquisition of\u00a0<a href=\"https:\/\/sense-bio.com\/\" target=\"_blank\" rel=\"noopener\">Sense Biodetection<\/a>, a global molecular\u202fdiagnostics innovator. The acquisition accelerates Sherlock\u2019s go-to-market strategy by adding Sense\u2019s Veros\u2122 instrument-free rapid molecular test platform and manufacturing capabilities, enabling the vision of highly accurate and affordable diagnostics that can be used anytime, anywhere. Terms of the acquisition are not being disclosed.<\/span><\/p>\n<p>\u201cThis acquisition accelerates Sherlock\u2019s ability to put the most advanced CRISPR-based diagnostics conveniently in the hands of global consumers,\u201d said\u00a0<strong>Bryan Dechairo, President and CEO of Sherlock Biosciences<\/strong>. \u201cThe Sense team has done a great job developing and validating their instrument-free diagnostic technology. Together, we can significantly push forward our go-to-market strategy by leveraging Sense\u2019s innovative chemistry and device engineering, combined with our industry-leading molecular technologies to realize our collective vision of democratizing and decentralizing diagnostics.\u201d<\/p>\n<p><span class=\"text-small\">Sense received its CE Mark in March 2022 for its Veros COVID-19 rapid, instrument-free molecular test, demonstrating strong clinical performance with high sensitivity and specificity. Coupled with Sherlock\u2019s proprietary engineering biology tools, including the first FDA-authorized use of CRISPR technology, this transaction enables Sherlock to bring highly accurate, advanced, handheld tests to global consumers for a wide range of diseases from respiratory and sexual health to global health outbreak response. Sherlock will integrate Sense\u2019s chemistry, manufacturing and technology into its platform, leveraging the company\u2019s proven development and regulatory experience to expand the capabilities of the Sherlock platform and drive further innovation.<\/span><\/p>\n<p>\u201cThis is a powerful combination of proprietary and leading technologies and will allow Sense to realize our vision of delivering the future of diagnostic testing to transform healthcare,\u201d said\u00a0<strong>Timothy Still, CEO of Sense<\/strong>. \u201cJoining Sherlock with their novel CRISPR technology was an excellent opportunity and we look forward to advancing our platform to meet the need for testing wherever and whenever it is needed.\u201d<\/p>\n<p><span class=\"text-small\">Sense is headquartered in Oxford, UK with facilities in Cambridge, UK and Milford, MA. Sense launched its first product, Veros COVID-19, in select European and South American markets, and is actively developing a portfolio of tests for other infectious diseases, complementing Sherlock\u2019s mission to develop diagnostic products that improve human health.<\/span><\/p>\n<p><span class=\"text-small\">\u201cThe potential for this acquisition to impact global health is significant,\u201d added Paul Meister, Partner at Sherlock investor Novalis LifeSciences, and previously Chairman of Thermo Fisher Scientific. \u201cThere\u2019s been a lot of speculation that 2023 will see increased M&amp;A activity in the life sciences industry; it\u2019s impressive that Sherlock is leading this trend in the private market.\u201d<\/span><\/p>\n<p><span class=\"text-small\">About Sherlock Biosciences<\/span><\/p>\n<p><span class=\"text-small\">Sherlock Biosciences is developing products that will empower people to access answers and have more control over their health decisions. Through our engineering biology tools, CRISPR-based SHERLOCK\u2122 and synthetic biology-based INSPECTR\u2122, we are bringing together the accuracy of PCR with the convenience and simplicity of antigen tests for molecular diagnostics at the point-of-need. SHERLOCK and INSPECTR can be used in virtually any setting without complex instrumentation, making it well suited for use in the home and in low-resource settings, opening up a wide range of potential applications in areas including infectious disease, early detection of cancer, treatment monitoring, and precision medicine. In 2020 the company made history with the first FDA-authorized use of CRISPR technology. For more information, please visit www.sherlock.bio.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sherlock Biosciences, a company engineering biology to bring next-generation diagnostics to the point of need, today announced the acquisition of\u00a0Sense Biodetection, a global molecular\u202fdiagnostics innovator. The acquisition accelerates Sherlock\u2019s go-to-market strategy by adding Sense\u2019s Veros\u2122 instrument-free rapid molecular test platform and manufacturing capabilities, enabling the vision of highly accurate and affordable diagnostics that can be [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":1663,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[6,29],"tags":[49],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Sense announces agreement to be acquired by Sherlock Biosciences - Cambridge Innovation Capital<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cic.vc\/sense-announces-agreement-to-be-acquired-by-sherlock-biosciences\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sense announces agreement to be acquired by Sherlock Biosciences - Cambridge Innovation Capital\" \/>\n<meta property=\"og:description\" content=\"Sherlock Biosciences, a company engineering biology to bring next-generation diagnostics to the point of need, today announced the acquisition of\u00a0Sense Biodetection, a global molecular\u202fdiagnostics innovator. The acquisition accelerates Sherlock\u2019s go-to-market strategy by adding Sense\u2019s Veros\u2122 instrument-free rapid molecular test platform and manufacturing capabilities, enabling the vision of highly accurate and affordable diagnostics that can be [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cic.vc\/sense-announces-agreement-to-be-acquired-by-sherlock-biosciences\/\" \/>\n<meta property=\"og:site_name\" content=\"Cambridge Innovation Capital\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-01T11:56:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-16T12:26:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/2020_03_31-Sense-Veros-Product-Image-v2-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1920\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lewis Harrison-Pinder\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@cic_vc\" \/>\n<meta name=\"twitter:site\" content=\"@cic_vc\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lewis Harrison-Pinder\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cic.vc\/sense-announces-agreement-to-be-acquired-by-sherlock-biosciences\/\",\"url\":\"https:\/\/www.cic.vc\/sense-announces-agreement-to-be-acquired-by-sherlock-biosciences\/\",\"name\":\"Sense announces agreement to be acquired by Sherlock Biosciences - Cambridge Innovation Capital\",\"isPartOf\":{\"@id\":\"https:\/\/www.cic.vc\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cic.vc\/sense-announces-agreement-to-be-acquired-by-sherlock-biosciences\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cic.vc\/sense-announces-agreement-to-be-acquired-by-sherlock-biosciences\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/2020_03_31-Sense-Veros-Product-Image-v2-scaled.jpg\",\"datePublished\":\"2023-02-01T11:56:22+00:00\",\"dateModified\":\"2024-04-16T12:26:37+00:00\",\"author\":{\"@id\":\"https:\/\/www.cic.vc\/#\/schema\/person\/01f4144d50b30601928e7ad98fcf6cbc\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.cic.vc\/sense-announces-agreement-to-be-acquired-by-sherlock-biosciences\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cic.vc\/sense-announces-agreement-to-be-acquired-by-sherlock-biosciences\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.cic.vc\/sense-announces-agreement-to-be-acquired-by-sherlock-biosciences\/#primaryimage\",\"url\":\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/2020_03_31-Sense-Veros-Product-Image-v2-scaled.jpg\",\"contentUrl\":\"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/2020_03_31-Sense-Veros-Product-Image-v2-scaled.jpg\",\"width\":2560,\"height\":1920},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cic.vc\/sense-announces-agreement-to-be-acquired-by-sherlock-biosciences\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cic.vc\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sense announces agreement to be acquired by Sherlock Biosciences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cic.vc\/#website\",\"url\":\"https:\/\/www.cic.vc\/\",\"name\":\"Cambridge Innovation Capital\",\"description\":\"We enable visionaries to build global, category-leading companies.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cic.vc\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cic.vc\/#\/schema\/person\/01f4144d50b30601928e7ad98fcf6cbc\",\"name\":\"Lewis Harrison-Pinder\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.cic.vc\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f8cbba69da3995ffe9ee74c57f0a6637?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f8cbba69da3995ffe9ee74c57f0a6637?s=96&d=mm&r=g\",\"caption\":\"Lewis Harrison-Pinder\"},\"url\":\"https:\/\/www.cic.vc\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sense announces agreement to be acquired by Sherlock Biosciences - Cambridge Innovation Capital","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cic.vc\/sense-announces-agreement-to-be-acquired-by-sherlock-biosciences\/","og_locale":"en_GB","og_type":"article","og_title":"Sense announces agreement to be acquired by Sherlock Biosciences - Cambridge Innovation Capital","og_description":"Sherlock Biosciences, a company engineering biology to bring next-generation diagnostics to the point of need, today announced the acquisition of\u00a0Sense Biodetection, a global molecular\u202fdiagnostics innovator. The acquisition accelerates Sherlock\u2019s go-to-market strategy by adding Sense\u2019s Veros\u2122 instrument-free rapid molecular test platform and manufacturing capabilities, enabling the vision of highly accurate and affordable diagnostics that can be [&hellip;]","og_url":"https:\/\/www.cic.vc\/sense-announces-agreement-to-be-acquired-by-sherlock-biosciences\/","og_site_name":"Cambridge Innovation Capital","article_published_time":"2023-02-01T11:56:22+00:00","article_modified_time":"2024-04-16T12:26:37+00:00","og_image":[{"width":2560,"height":1920,"url":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/2020_03_31-Sense-Veros-Product-Image-v2-scaled.jpg","type":"image\/jpeg"}],"author":"Lewis Harrison-Pinder","twitter_card":"summary_large_image","twitter_creator":"@cic_vc","twitter_site":"@cic_vc","twitter_misc":{"Written by":"Lewis Harrison-Pinder","Estimated reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cic.vc\/sense-announces-agreement-to-be-acquired-by-sherlock-biosciences\/","url":"https:\/\/www.cic.vc\/sense-announces-agreement-to-be-acquired-by-sherlock-biosciences\/","name":"Sense announces agreement to be acquired by Sherlock Biosciences - Cambridge Innovation Capital","isPartOf":{"@id":"https:\/\/www.cic.vc\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cic.vc\/sense-announces-agreement-to-be-acquired-by-sherlock-biosciences\/#primaryimage"},"image":{"@id":"https:\/\/www.cic.vc\/sense-announces-agreement-to-be-acquired-by-sherlock-biosciences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/2020_03_31-Sense-Veros-Product-Image-v2-scaled.jpg","datePublished":"2023-02-01T11:56:22+00:00","dateModified":"2024-04-16T12:26:37+00:00","author":{"@id":"https:\/\/www.cic.vc\/#\/schema\/person\/01f4144d50b30601928e7ad98fcf6cbc"},"breadcrumb":{"@id":"https:\/\/www.cic.vc\/sense-announces-agreement-to-be-acquired-by-sherlock-biosciences\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cic.vc\/sense-announces-agreement-to-be-acquired-by-sherlock-biosciences\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.cic.vc\/sense-announces-agreement-to-be-acquired-by-sherlock-biosciences\/#primaryimage","url":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/2020_03_31-Sense-Veros-Product-Image-v2-scaled.jpg","contentUrl":"https:\/\/www.cic.vc\/wp-content\/uploads\/2023\/04\/2020_03_31-Sense-Veros-Product-Image-v2-scaled.jpg","width":2560,"height":1920},{"@type":"BreadcrumbList","@id":"https:\/\/www.cic.vc\/sense-announces-agreement-to-be-acquired-by-sherlock-biosciences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cic.vc\/"},{"@type":"ListItem","position":2,"name":"Sense announces agreement to be acquired by Sherlock Biosciences"}]},{"@type":"WebSite","@id":"https:\/\/www.cic.vc\/#website","url":"https:\/\/www.cic.vc\/","name":"Cambridge Innovation Capital","description":"We enable visionaries to build global, category-leading companies.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cic.vc\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/www.cic.vc\/#\/schema\/person\/01f4144d50b30601928e7ad98fcf6cbc","name":"Lewis Harrison-Pinder","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.cic.vc\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f8cbba69da3995ffe9ee74c57f0a6637?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f8cbba69da3995ffe9ee74c57f0a6637?s=96&d=mm&r=g","caption":"Lewis Harrison-Pinder"},"url":"https:\/\/www.cic.vc\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts\/1527"}],"collection":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/comments?post=1527"}],"version-history":[{"count":3,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts\/1527\/revisions"}],"predecessor-version":[{"id":2970,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/posts\/1527\/revisions\/2970"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/media\/1663"}],"wp:attachment":[{"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/media?parent=1527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/categories?post=1527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cic.vc\/wp-json\/wp\/v2\/tags?post=1527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}